FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer
The label expansion for Boehringer Ingelheim’s Hernexeos was made under an FDA pilot program that accelerates regulatory review of products with national interest. The daily pill is now approved as a first-line treatment for HER2-positive non-small lung cancer, an indication with few treatment options.